 This is an investigational study. Ruxolitinib is FDA approved and commercially available for the treatment of myelofibrosis. Its use in this study is investigational. The study doctor can explain how ruxolitinib is designed to work. Dasatinib is FDA approved and commercially available for the treatment of CML and Philadelphia chromosome-positive ALL. All other drugs used in this study are FDA approved and commercially available. Their use together in this study is investigational. The study doctor can explain how the study drugs are designed to work. 